Evofem Biosciences, Inc. (EVFM) stock: key figures, P/E, revenue and dividend
Health Care · United States · ISIN US30048L3024
Evofem Biosciences, Inc. financials
| Fiscal year | 2025 |
|---|---|
| Revenue | 20.18 m USD |
| Gross profit | 15.57 m USD |
| Operating income | 3.37 m USD |
| EBIT | 2.74 m USD |
| Net income | 391,000.00 USD |
| Diluted EPS – continuing operations | 0.00 USD |
Full history since 2012, charts and your own formulas
This page shows the last two fiscal years. After free sign-up you get the full income statement, balance sheet and cash flow, price and dividend charts, your own formula metrics and a stock screener covering more than 8,000 companies.
About Evofem Biosciences, Inc.
Evofem Biosciences, Inc., a biopharmaceutical company, develops and commercializes various products to address unmet needs in women's sexual and reproductive health. The company's commercial products include PHEXXI, a hormone-free contraceptive vaginal gel; and SOLOSEC, a single-dose oral antimicrobial agent for the treatment of bacterial vaginosis and trichomoniasis. Evofem Biosciences, Inc. is headquartered in San Diego, California.
More stocks
- Mentor Capital, Inc. (MNTR)
- ProtoKinetix, Inc. (PKTX)
- Athena Bitcoin Global (ABIT)
- Protagenic Therapeutics, Inc.\new (PTIX)
- Everything Blockchain, Inc. (EBZT)
- My Size, Inc. (MYSZ)
- Nu-Med Plus, Inc. (NUMD)
- GENERATION INCOME PROPERTIES, INC. (GIPR)
- Sky Century Investment, Inc. (SKYI)
- Dream Homes & Development Corp. (DREM)
- Yubo International Biotech Ltd (YBGJ)
- iPower Inc. (IPW)
Not investment advice. All data without warranty, price as of 13.11.2026. Details in the risk notice.